Market Research Industry Reports

Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2018

  • DESCRIPTION
  • TABLE OF CONTENTS
  • RELATED REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2018

Summary

GlobalDatas clinical trial report, Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2018" provides an overview of Non Alcoholic Fatty Liver Disease (NAFLD) clinical trials scenario. This report provides top line data relating to the clinical trials on Non Alcoholic Fatty Liver Disease (NAFLD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Non Alcoholic Fatty Liver Disease (NAFLD) 31
Apr 09, 2018: Can-Fite to Present the Anti-Inflammatory and Anti-Fibrogenic Effects of Namodenoson in NAFLD/NASH Pre-clinical Studies at the 2018 International Liver Congress of the European Association for the Study of the Liver (EASL) 31
Apr 03, 2018: Inventiva Announces a U.S. Phase II Investigator-Initiated Study with Lanifibranor on Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes 31
Apr 01, 2018: MediciNova Announces Phase 2 Trial of MN-001 (tipelukast) in NASH / NAFLD will be Terminated Early based on Significant Positive Results from Interim Analysis 31
Mar 18, 2018: Diabetes medicine reduces liver fat in nonalcoholic fatty liver disease 32
Mar 14, 2018: Can-Fite to Present at the NASH 2nd Annual H.C. Wainwright Investor Conference 32
Mar 08, 2018: Gastrointestinal Hormone Measurably Improved Symptoms of Non-Alcoholic Fatty Liver Disease 33
Mar 07, 2018: Cerenis Therapeutics Announces Approval to launch the Phase I Study of repeated and increasing doses to assess CER-209 in NASH/NAFLD 33
Mar 06, 2018: Can-Fite to Provide Update on Liver Drug Namodenoson at the 30th Annual ROTH Conference 34
Feb 28, 2018: Can Fite Reports on the Progress of its Phase II NASH Study with Drug Candidate Namodenoson 34
Feb 22, 2018: Can Fite Announces the Submission of Safety Reports for Namodenoson to FDA and other Regulatory Authorities 34
Feb 12, 2018: Can-Fite BioPharma Announces New Pre-Clinical Data Supporting a Novel Anti-NASH Mechanism of Action for Namodenoson 35
Jan 31, 2018: Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease 35
Jan 28, 2018: MediciNova Announces MN-001 (tipelukast) NASH/NAFLD Phase 2 Trial Interim Results Selected for Presentation at the International Liver Congress 2018 in Paris, France 37
Clinical Trial Profile Snapshots 38
Appendix 293
Abbreviations 293
Definitions 293
Research Methodology 294
Secondary Research 294
About GlobalData 295
Contact Us 295
Source 295

List Of Tables

List of Tables
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region, 2018* 8
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2018* 14
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2018* 15
Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, G7 Countries (%), 2018* 16
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E7 Countries (%), 2018* 19
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Phase, 2018* 22
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30

List Of Figures

List of Figures
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Region (%), 2018* 8
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2018* 14
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2018* 15
Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, G7 Countries (%), 2018* 16
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
Proportion of Non Alcoholic Fatty Liver Disease (NAFLD) to Gastrointestinal Clinical Trials, E7 Countries (%), 2018* 19
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30
GlobalData Methodology 294

2018 Lebanon Nucleic Acid Testing (NAT) Market: Supplier Shares and Strategies, Country Volume and Sales Segment Forecasts--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing

This new report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the molecular diagnostics market during the next five years.Highlights- Five-year test

USD 4250View Report

2018 Lebanon Virology and Bacteriology Testing Market: Supplier Shares and Strategies, Test Volume and Sales Forecasts, Technology and Instrumentation Review

This new report is designed to help current suppliers and potential market entrants identify and evaluate business opportunities emerging in the infectious disease testing market during the next five years.

USD 4500View Report

Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018

Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018This report provides an overview of the non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)

USD 3995View Report

Non Alcoholic Fatty Liver Disease (NAFLD) - Market Insight, Epidemiology and Market Forecast - 2027

DelveInsights Non Alcoholic Fatty Liver Disease (NAFLD) - Market Insight, Epidemiology and Market Forecast - 2027 report provides a detailed analysis of the Non Alcoholic Fatty Liver Disease (NAFLD)

USD 6250View Report

Your are not allow to send sample request
Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2500
  • Site Licence    USD 5000
  • Enterprise Wide Licence    USD 7500
$ 2500

Reports Details

Published Date : Mar 2018
No. of Pages :295
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :GlobalData
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube